VEGF Receptor Fusion Protein SEC Purification for Cathepsin D Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing and purifying VEGF receptor fusion proteins, such as aflibercept, fail to adequately remove impurities and maintain high purity, leading to inefficiencies in the manufacturing process, which can adversely affect the safety and efficacy of the drug.
Innovation Solution
A process involving size exclusion chromatography (SEC) is used to purify VEGF receptor fusion proteins, such as aflibercept, by flowing a drug substance intermediate through an SEC column, collecting an eluate with less than 1 ppm of aspartyl protease, such as cathepsin D, and excluding impurities, thereby enhancing the purity of the formulations, and formulations with a high concentration of aflibercept and low concentration of cathepsin D.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods are used for VEGF receptor fusion proteins, then the manufacturing process is simpler, but the purity of the final product is insufficient
Solution Approach 1:
The purification process is divided into multiple sequential chromatography steps (affinity chromatography, ion exchange chromatography, and size exclusion chromatography), where each step targets specific impurities. This segmentation allows systematic removal of different impurity types while maintaining manageable process complexity through modular design
Solution Approach 2:
The patent introduces intermediate purification steps with specific buffers and conditions that facilitate selective impurity removal. These intermediates act as mediators between the crude extract and final purified product, enabling gradual purification while monitoring quality at each stage
2Manufacturing precision
If multiple purification steps are implemented to remove impurities, then the purity of VEGF receptor fusion protein increases, but the manufacturing time and cost increase
Solution Approach 1:
The methodology performs preliminary purification actions early in the process using affinity chromatography to remove bulk impurities before subsequent refinement steps. This preliminary action reduces the burden on later steps and prevents impurity accumulation, saving overall processing time
Solution Approach 2:
The purification steps are designed to operate in continuous sequence without interruption, maintaining flow and preventing stagnation. Each chromatography step transitions directly to the next, ensuring continuous removal of impurities and maximizing manufacturing efficiency while achieving high purity
3Reliability
If conventional purification methods are used, then the manufacturing cost is lower, but the safety and efficacy of the drug are compromised
Solution Approach 1:
The patent incorporates quality control checkpoints and analytical methods at each purification stage to monitor purity levels. This feedback mechanism ensures that impurities are removed to predetermined limits, guaranteeing drug safety and efficacy while optimizing resource allocation to avoid unnecessary additional purification steps
Solution Approach 2:
The methodology systematically adjusts critical process parameters (pH, ionic strength, flow rate, temperature) at each purification step to optimize impurity removal efficiency. These parameter changes maximize purification effectiveness while controlling manufacturing costs through precise process optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a high concentration of aflibercept with a low concentration of cathepsin D, enhancing the purity and quality of the formulations, thus improving the efficacy and safety of the drug, by reducing the impurities, thereby improving the efficacy and safety of the drug, ensuring high-purity formulations and formulations, thus improving the efficacy and safety of the drug.
Implementation Method 1
A process involving size exclusion chromatography (SEC) is used to purify VEGF receptor fusion proteins
Data Source
AI summary
Anti-VEGF proteins including the VEGF trap protein aflibercept can be produced to have a low level of an aspartyl protease (e.g., a low level of cathepsin D), such as less than 1 ppm of the aspartyl protease.